GLG News by Acupuncture Providers (US)

The trial design by YM BioSciences USA (YM), using nimotuzumab, is a simple, easy to monitor study. With a preliminary rate of Partial Response (PR) and Stable Disease (SD) at 21 weeks of 14%; a better than significant number. The concern may be in the potential for side-effects that may be understated,...

With hospital-acquired infections held to be a leading cause of US deaths each year it may be a good idea to create an incentive rather than a punishment, to remedy the problem. Medicare patients are generally the more frail population and require competent, quality care. Policy makers may be unwittingly...

Chronic diseases has been around for centuries, our tools need to evolve, now. Charts published by World Health Organization compared the Global Chronic Disease Burden Years 1990 to 2020. In an IBLF dialogue with WHO, London, 28, October 2002, it was stated 49% of the Global Chronic Disease...

When chemicals are required to intervene in complex physical functions such as digestion and conversion of food to energy, a warning of the possible side effects is essential. Many individuals are uninformed about the process of food conversion, caloric energy values, glucose utilization,...